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ARTICLE
Multiple myeloma gammopathies
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Abstract
Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines
represent a clinically important population in need of effective therapies. The safety and efﬁcacy of pomalidomide, low-dose
dexamethasone, and daratumumab was evaluated in lenalidomide-pretreated patients with relapsed or refractory multiple
myeloma (RRMM) after one to two prior treatment lines in the phase 2 MM-014 study. Patients received pomalidomide
4 mg daily from days 1–21 and dexamethasone 40 mg weekly (28-day cycles). Daratumumab 16 mg/kg was administered
per label. Primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS)
and safety. Per protocol, all patients (N = 112) had received lenalidomide in their most recent prior regimen (75.0%
lenalidomide refractory). ORR was 77.7% (76.2% in lenalidomide-refractory patients); median follow-up was 17.2 months.
Median PFS was not reached (1-year PFS rate 75.1%). The most common hematologic grade 3/4 treatment-emergent
adverse event was neutropenia (62.5%). Grade 3/4 infections were reported in 31.3% of patients, including 13.4% with grade
3/4 pneumonia. These results demonstrate the safety and efﬁcacy of pomalidomide-based therapy as early as second line in
patients with RRMM, even immediately after lenalidomide failure, indicating that switching from the immunomodulatory
agent class is not necessary.
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lenalidomide-based regimens, patients with lenalidomiderefractory disease have been poorly represented in recent
phase 3 relapsed or refractory MM (RRMM) clinical trials
[1, 4–9]. Management of these patients remains challenging
due to the availability of multiple treatment options combined with factors such as disease aggressiveness, patient
age, and response to previous antimyeloma therapies
[3, 10]. In addition, effective treatment of early RRMM is
critical because patient outcomes worsen with each relapse,
and the interval between relapses shortens with each subsequent line of treatment [2, 3, 11]. Therefore, patients who
have become refractory to lenalidomide in early treatment
lines are a clinically relevant population in need of proven
and effective therapies [1, 4–9].
Pomalidomide, an immunomodulatory agent, exerts
potent, direct tumoricidal, and immune-stimulating effects
through binding to its molecular target cereblon, a component of the CRL4 E3 ubiquitin ligase, and subsequent
degradation of the transcription factors Ikaros and Aiolos
[12, 13]. The antitumor and immune-stimulating properties
of pomalidomide are distinct from those of lenalidomide;
pomalidomide has different substrate degradation kinetics,
increased binding afﬁnity to cereblon, and a different gene
modulation proﬁle [12–15]. Pomalidomide also has activity
in lenalidomide-resistant myeloma cell lines and animal
models and has demonstrated efﬁcacy in patients refractory
to lenalidomide in clinical trials [13, 14, 16–20].
Pomalidomide was initially approved in combination
with dexamethasone for the treatment of patients with
RRMM and ≥2 prior therapies (including lenalidomide and
a proteasome inhibitor in the United States and lenalidomide and bortezomib in the European Union) [21, 22].
More recently, various pomalidomide-based triplet regimens have received regulatory approval. The combination
of pomalidomide, dexamethasone, and daratumumab is
approved in the United States for the same indication as the
doublet regimen, as is the combination of pomalidomide,
dexamethasone, and elotuzumab [23, 24]. Findings from the
recent phase 3 OPTIMISMM trial that demonstrated a
signiﬁcantly prolonged progression-free survival (PFS) with
pomalidomide, bortezomib, and dexamethasone (PVd) vs
Vd (11.2 vs 7.1 months; HR, 0.61 [95% CI, 0.49–0.77]; p <
0.001) in patients with one to three prior regimens recently
led to approval of PVd in several jurisdictions, including in
the European Union and Japan, for the treatment of patients
with RRMM who received ≥1 prior regimen [21, 25, 26].
Daratumumab, an anti-CD38 monoclonal antibody, exerts
direct on-tumor and immunomodulatory activity [27–30].
Daratumumab was approved in the United States for the
treatment of RRMM in combination with pomalidomide and
dexamethasone based on results of the phase 1b EQUULEUS/MMY1001 RRMM trial [23, 31]. In this study of
patients with heavily pretreated RRMM (median, four prior
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lines of therapy), the triplet combination led to an overall
response rate (ORR) of 60%, including an ORR of 58% in
patients who were refractory to both a proteasome inhibitor
(PI) and an immunomodulatory agent [31]. Median PFS
was 8.8 months, and median overall survival (OS) was
17.5 months. However, this regimen has not been extensively
studied in earlier lines of therapy or in patients who became
refractory to lenalidomide-based therapy immediately prior to
study entry.
The phase 2 MM-014 trial investigated the outcomes of
sequencing pomalidomide-based therapy immediately after
lenalidomide failure in early treatment lines. Here we report
safety and efﬁcacy ﬁndings from cohort B, in which
patients relapsed from or refractory to lenalidomide in their
ﬁrst or second treatment line received pomalidomide, lowdose dexamethasone, and daratumumab.

Methods
Study design and patients
MM-014 is a phase 2, nonrandomized, multicenter, openlabel clinical trial with three cohorts conducted at 49 study
sites in the United States, Canada, and Japan. Patients in
cohort A received pomalidomide plus low-dose dexamethasone. Patients in cohort B received pomalidomide,
low-dose dexamethasone, and daratumumab. Cohort C
(currently enrolling) is a Japanese-only arm of the study;
patients will receive pomalidomide, low-dose dexamethasone, and daratumumab. Patients were not allocated
across cohorts; rather, cohort B was added to the trial via
protocol amendment after the full accrual of cohort A, and
cohort C was added after the full accrual of cohort B.
Patients eligible for inclusion in cohort B of MM-014
were ≥18 years of age with documented MM diagnosis,
measurable disease (serum M-protein ≥0.5 g/dl or urine Mprotein ≥200 mg/24 h), and Eastern Cooperative Oncology
Group performance status ≤2. In addition, patients were
required to have had one or two prior lines of antimyeloma
therapy, documented progressive disease (PD) during or
after their last line of therapy, and treatment with a
lenalidomide-containing regimen for ≥2 consecutive cycles
as their most recent regimen. Patients who relapsed after or
were refractory to lenalidomide were eligible for inclusion.
Refractory disease was deﬁned as nonresponsive to therapy
or as PD within 60 days of the last dose.
Key exclusion criteria included prior treatment with
pomalidomide or daratumumab or hypersensitivity to
thalidomide, lenalidomide, dexamethasone, or monoclonal
antibodies. The following laboratory abnormalities were
exclusionary: absolute neutrophil count <1 × 109/l, platelet
count <75 × 109/l (<30 × 109/l for patients in whom ≥50%
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of bone marrow nucleated cells were plasma cells),
corrected serum calcium >2.875 mmol/l (11.5 mg/dl),
hemoglobin <80 g/l, aspartate aminotransferase or alanine
transaminase >3.0 × upper limit of normal, serum total
bilirubin >34.2 µmol/l (2.0 mg/dl) or 3.0 × upper limit of
normal, and severe renal impairment (creatinine clearance
<30 ml/min or requiring dialysis).

Treatment
Patients received pomalidomide, low-dose dexamethasone,
and daratumumab in 28-day cycles until PD or unacceptable toxicity. Both pomalidomide and low-dose dexamethasone were administered orally, and daratumumab
was administered intravenously. Pomalidomide 4 mg was
given on days 1 to 21. Dexamethasone 40 mg (20 mg for
patients >75 years of age) was given on days 1, 8, 15, and
22. Daratumumab 16 mg/kg was given on days 1, 8, 15,
and 22 of cycles 1 and 2; days 1 and 15 for cycles 3
through 6; and day 1 for cycle 7 and beyond. Daratumumab
dose reductions were not allowed. Thromboprophylaxis
was mandatory for all patients and included low-dose
aspirin, low-molecular-weight heparin, or other equivalent
antithrombotic agents.
Patients experiencing grade 4 neutropenia or febrile
neutropenia had their dose of pomalidomide modiﬁed.
Following an event, the dose was withheld and complete
blood counts were followed weekly. If the patient was not
already receiving granulocyte-colony stimulating factor (GCSF), the treating physician could initiate G-CSF at their
discretion. Absolute neutrophil counts were required to be
≥500 cells/μl prior to restarting pomalidomide.

Endpoints and assessments
The primary endpoint was ORR. Secondary endpoints were
time to response (TTR), duration of response (DOR), PFS,
time to progression (TTP), OS, and safety, including
adverse events (AEs) and second primary malignancies
(SPMs). Exploratory endpoints for cohort B included
molecular, immune, and cellular markers potentially predictive of response or resistance to treatment, pharmacodynamic and mechanistic biomarkers, and health-related
quality of life (HRQOL).
Tumor response was based on investigator’s assessment
using local imaging review (if applicable) and central
laboratory results according to modiﬁed International
Myeloma Working Group criteria. Daratumumab-speciﬁc
serum immunoﬁxation electrophoresis reﬂex assay was
performed per protocol for patients with immunoglobulin-ɣ
(IgG) and -κ MM and monoclonal spike of ≤0.2 g/dl. TTR,
DOR, TTP, and PFS were calculated based on the investigator’s response assessment, and all time-to-event endpoints
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were estimated from time of study enrollment, except DOR,
which was estimated from time of response. Efﬁcacy
assessments included myeloma paraprotein, serum immunoglobulins, serum free light chain, bone marrow aspiration
and/or biopsy, radiographic assessments of lytic bone
lesions, and extramedullary plasmacytoma assessments.
Safety assessments included AEs, physical examination,
clinical laboratory evaluations, venous thromboembolism
monitoring, and pregnancy testing and counseling. AEs
were coded according to Medical Dictionary for Regulatory
Activities (version 20.0) and graded according to National
Cancer Institute Common Terminology Criteria for Adverse
Events (version 4.03). If a patient experienced the same AE
multiple times, only the event of worst severity was counted. SPMs were monitored as events of interest and reported
as serious AEs.
HRQOL was assessed via EuroQol EQ-5D at baseline, at
day 1 of each treatment cycle prior to treatment administration, and at treatment discontinuation. In addition, the
worst change from screening among all postbaseline measurements was analyzed. Overall scores were analyzed
using change from baseline assessment at each postbaseline
time point using a mixed model with adjustment for baseline covariates.
All patients provided bone marrow aspirate, whole
blood, saliva, and normal tissue samples. Baseline and ontreatment peripheral blood samples were collected to evaluate comprehensive immune proﬁles, including T-cell and
NK-cell subset data. All laboratory measures for safety and
efﬁcacy assessments were performed centrally, but tests that
could result in dose modiﬁcations were also performed
locally to facilitate treatment-related decisions during
patient visits. Local laboratory results were not collected
unless speciﬁcally requested by the sponsor.

Statistical analysis
The intention-to-treat (ITT) population, deﬁned as all
enrolled patients regardless of whether they received study
treatment, was used for all efﬁcacy analyses. The efﬁcacy
evaluable (EE) population, comprising enrolled patients
who received ≥1 dose of study treatment and had ≥1 postbaseline response assessment, was used to provide supportive sensitivity analyses for ORR, PFS, and OS. The
safety population was deﬁned as all enrolled patients who
received ≥1 dose of study treatment. The HRQOL-evaluable
population comprised patients who had baseline HRQOL
evaluation and ≥1 postbaseline evaluation.
Baseline and demographic characteristics were summarized via frequency tabulations for categorical variables
and descriptive statistics for continuous variables. For
cohort B, a sample size of ~100 patients was deemed adequate to estimate ORR with a 95% CI of width ±9.7% about
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the obtained rate. Point estimates of ORR together with the
95% CI were calculated using normal approximation to the
binomial distribution. Kaplan–Meier procedures were used
to characterize time-to-event curves; medians and 95% CIs
were estimated. Univariate summary statistics were provided for TTR.
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Table 1 Demographic and baseline characteristics.
Characteristic

ITT population
(N = 112)

Age, median (range), years

66.5 (39.0–83.0)

>65 years, n (%)
Male, n (%)

62 (55.4)
76 (67.9)

ECOG PS, n (%)

Study oversight
All patients provided written informed consent. This study
was carried out in accordance with the principles of the
Declaration of Helsinki and the International Conference on
Harmonisation’s Guideline for Good Clinical Practice as
well as applicable local regulations governing conduct of
clinical studies. Each participating site’s institutional review
board or ethics committee approved the study. This study
was funded and sponsored by Bristol-Myers Squibb. The
study’s sponsor compiled and maintained the data. All
authors had full access to the data. This study was registered
at ClinicalTrials.gov as NCT01946477.

0

44 (39.3)

1

67 (59.8)

2

1 (0.9)

Calculated R-ISS stage, n (%)
I

30 (26.8)

II

53 (47.3)

III

8 (7.1)

NE

21 (18.8)

Time from MM diagnosis, median
(range), years
Number of prior antimyeloma lines,
median (range)

3.4 (0.5–11.6)
1 (1–2)

One prior line of therapy, n (%)

70 (62.5)

Two prior lines of therapy, n (%)

42 (37.5)

Prior therapies, n (%)

Results

LEN
Proteasome inhibitora

Cohort B included 112 patients enrolled between September
2016 and December 2017 (Fig. 1). Median age was 66.5
years, and most patients (67.9%) were male (Table 1). The
median time since MM diagnosis was 3.4 years. Per protocol, patients had either one (n = 70; 62.5%) or two prior
lines of therapy (n = 42; 37.5%), and all patients were
treated with lenalidomide in the immediate prior line of

Excluded (n = 22)
• Eligibility criteria not met (n = 22)
• Declined to parcipate (n = 0)
• Other reasons (n = 0)

87 (77.7)

CFZ

11 (9.8)

IXA

89 (79.5)

SCT

78 (69.6)

Other agents

Duration of most recent prior LENcontaining regimen, median
(range), months

8 (7.1)b
84 (75.0)
23.9 (0.4–116.8)

Most recent prior LEN dose, n (%)

Allocated to intervenon (n = 112)
• Received allocated intervenon (n = 112)
• Did not receive allocated intervenon (n = 0)

Disconnued intervenon (n = 63): disease progression (n = 33), paent
withdrawal (n = 17), adverse event (n = 4), other (n = 4), death (n = 2), missing
(n = 2), transion to commercially available treatment (n = 1)

4 (3.6)

Alkylating agents

25 mg

Lost to follow-up (n = 0)

89 (79.5)

BORT

Refractory to most recent prior LENcontaining regimen, n (%)c

Assessed for eligibility (n = 134)

112 (100)

35 (31.3)

20 mg

4 (3.6)

15 mg

18 (16.1)

≤10 mg

54 (48.2)

Missing

1 (0.9)

BORT bortezomib, CFZ carﬁlzomib, ECOG PS Eastern Cooperative
Oncology Group performance status, ITT intention-to-treat, IXA
ixazomib, LEN lenalidomide, MM multiple myeloma, NE not
evaluable, R-ISS revised International Staging System, SCT stem cell
transplant.
a

Patients may have received >1 proteasome inhibitor.

b
Analyzed (n = 112)
• Excluded from analysis (n = 0)

Fig. 1 CONSORT ﬂow diagram of cohort B of MM-014. Cohort B
enrolled 112 patients.

Including one patient who received doxorubicin, eight patients who
received etoposide, and three patients who received cisplatin. Patients
may have received >1 of these agents.

c
Refractoriness to lenalidomide was deﬁned as being refractory to the
lenalidomide-containing regimen immediately prior to study entry.
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therapy; 84 patients (75.0%) were refractory to lenalidomide. The most recent prior lenalidomide dose was ≤10 mg
in 54 patients (48.2%). Overall, 89 patients (79.5%) had
prior exposure to a PI; 87 patients (77.7%) had received
prior treatment with both lenalidomide and bortezomib.
Seventy-eight patients (69.6%) had undergone prior stem
cell transplant. Of 93 patients with available cytogenetic
analysis, 73 patients (78.5%) were classiﬁed as standard
risk, and 20 patients (21.5%) were classiﬁed as high risk
(presence of del[17p], t[4;14], and/or t[14;16]).
With a median follow-up of 17.2 months, 63 patients had
discontinued treatment at data cutoff (February 8, 2019),
and 49 patients remained on active treatment. PD was the
most common cause of discontinuation (n = 33), followed
by patient withdrawal (n = 17), AEs (n = 4), other reasons
(n = 4), death (n = 2), and transition to another commercially available treatment (n = 1); the reason for discontinuation was missing for two patients. Median duration
of treatment was 14.6 months for pomalidomide,
13.2 months for low-dose dexamethasone, and 14.4 months
for daratumumab (Supplementary Table 1). Median relative
dose intensity was 0.9, 0.8, and 1.0 for pomalidomide, lowdose dexamethasone, and daratumumab, respectively.
In the ITT population, 87 patients (77.7%) achieved
ORR; 57 (50.9%) achieved very good partial response
(VGPR) or better, and 27 patients (24.1%) achieved complete response (CR) (Table 2). In the EE population (n =
109), ORR was 79.8%. In both the ITT and EE populations,
median TTR was 1.0 month (range, 0.8–4.8 months), and
median time to best response was 3.7 months (range,
0.9–20.7 months). For most patients, depth of response
increased over time (Fig. 2); 37 patients (42.5%) did not
achieve their best response until ≥6 months. Median DOR

Table 2 Response (mIMWG criteria).
Response, n (%)

ITT population (N = 112)

CBR (MR or better)

96 (85.7)

ORR (PR or better)

87 (77.7)

CR

27 (24.1)

VGPR

30 (26.8)

PR

30 (26.8)

MR

9 (8.0)

SD

8 (7.1)

PD

5 (4.5)

NE

2 (1.8)

Missing

1 (0.9)

CBR clinical beneﬁt response, CR complete response, ITT intention-totreat, mIMWG modiﬁed International Myeloma Working Group, MR
minimal response, NE not evaluable, ORR overall response rate, PD
progressive disease, PR partial response, SD stable disease, VGPR
very good partial response.

was not reached in either the ITT or EE population; the
1-year DOR rate was 77.7% for both.
In general, ORR among analyzed subgroups was consistent with that of the ITT population (Fig. 3; Supplementary Table 2). The ORR reported in patients with one
prior line of therapy (78.6%) was similar to that observed
in patients with two prior lines of therapy (76.2%).
Patients who relapsed after or were refractory to lenalidomide had an ORR of 82.1% and 76.2%, respectively. In
patients whose last prior dose of lenalidomide was ≤10 mg
or >10 mg, 85.2% and 70.2% achieved ORR, respectively.
ORR was 78.7% in patients who had prior PI and lenalidomide exposure. Patients with standard-risk vs high-risk
cytogenetics had an ORR of 79.5% vs 55.0%, respectively.
In addition, ORR was 90.9% in patients treated with
lenalidomide for >24 months (n = 55) and 64.9% in
patients treated with lenalidomide for ≤24 months (n =
57). Notably, patients with calculated Revised International Staging System stage I disease (n = 30) achieved an
ORR of 93.3%.
Median PFS was not reached for the ITT (Fig. 4a) or EE
populations. The 1-year PFS rates were 75.1% and 75.9%,
respectively. In patients who relapsed after lenalidomide,
the 1-year PFS rate was 83.2%, while patients refractory to
lenalidomide had a median PFS of 21.8 months and a 1-year
PFS rate of 72.4%. Among patients whose last prior dose of
lenalidomide was ≤10 mg, 77.9% remained alive and progression free at 1 year compared with 71.9% of those whose
last prior dose of lenalidomide was >10 mg (Fig. 4b). In
patients with one vs two prior lines of therapy, the 1-year
PFS rate was 78.8% vs 69.0%, respectively (Supplementary
Fig. 1). In patients with prior PI and lenalidomide exposure,
75.4% were alive and progression free at 1 year (Supplementary Fig. 2). The 1-year PFS rate was 82.8% vs 45.2%
in patients with standard-risk vs high-risk cytogenetics,
respectively (Supplementary Fig. 3). In patients whose
duration of prior lenalidomide treatment was >24 vs
≤24 months, 1-year PFS rates were 85.6% vs 64.1%,
respectively. Median TTP was not reached in either the ITT
or EE population. OS data are not yet mature, with 20
deaths documented to date.
Measurable residual disease (MRD) assessments via
next-generation sequencing (LymphoTrack, Invivoscribe,
San Diego, CA) were performed in 19 patients with best
response of VGPR or better and matching screen and
response conﬁrmation timepoints. Trackable clones were
identiﬁed as >2.5% of all recombinant clonal sequences
from the CDR3 region in 16 of 19 patients (84.2%); three
patients did not have a clone sufﬁcient for indexing. Eight
of 16 patients were MRD negative (all <10−4 based on
cellularity and lowest limit of quantiﬁcation; three patients
had a lower limit of quantiﬁcation of 10−5). Twelve patients
achieved CR; of these patients, seven were MRD negative
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Fig. 2 Depth of response over
time in the ITT populationa.
For response missing ≤2 cycles
in the range from the ﬁrst
available response to the last
available response, the last
response assessment before the
gap was carried through the gap.
CR complete response, ITT
intention-to-treat, MR minimal
response, PD progressive
disease, PR partial response, SD
stable disease, VGPR very good
partial response. aExcludes 1
patient without response. bData
truncated due to discontinuation,
data cutoff, or start of new
treatment.

CR
VGPR
PR
MR
SD
PD
Data truncatedb
Death

C2

Fig. 3 Overall response rates
by subgroups. The vertical line
indicates 77.7%, which was the
ORR in the overall population.
CrCl creatinine clearance,
ECOG PS Eastern Cooperative
Oncology Group performance
status, HR high-risk, LCL lower
control limit, LEN lenalidomide,
ORR overall response rate, PI
proteasome inhibitor, R-ISS
Revised International Staging
System, SCT stem cell
transplant, SR standard risk, Tx
treatment, UCL upper
control limit.

C4

C6

C8

C10

C12

Subgroup

C14

C16

C18

C20

C22

ORR and 95% CI

Age ≤ 65 years
Age > 65 years
ECOG PS < 1
ECOG PS ≥ 1
Calculated R-ISS stage I
Calculated R-ISS stage II
Calculated R-ISS stage III
CrCl ≥ 30 to < 45 ml/min
CrCl ≥ 45 to < 60 ml/min
CrCl ≥ 60 ml/min
Prior SCT
No prior SCT
Triplet induction < 3 agents
Triplet induction ≥ 3 agents
Duration of prior LEN Tx ≤ 24 months
Duration of prior LEN Tx > 24 months
Dose of prior LEN Tx ≤ 10 mg
Dose of prior LEN Tx > 10 mg
1 prior Line
2 prior Lines
Relapsed after LEN
Refractory to LEN
Baseline serum β2 microglobulin: < 4 mg/l
Baseline serum β2 microglobulin: ≥ 4 mg/l
Prior LEN + PI
SR cytogenetic abnormalities
HR cytogenetic abnormalities
Overall
0

at ≥6 months after study entry. Furthermore, of four patients
with VGPR as best response, one patient was MRD negative. All eight MRD-negative patients and seven of eight
MRD-positive patients remain in remission, with a minimum follow-up time of 16 months.
Nearly all patients (99.1%) had a treatment-emergent
adverse event (TEAE). The most common nonhematologic
any-grade TEAE was infections and infestations (85 patients
[75.9%]), including 35 (31.3%) with upper respiratory tract
infection; the most common hematologic any-grade TEAE
was neutropenia (74 patients [66.1%]). Any-grade infusionrelated reactions were reported in 34 patients (30.4%).
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C24

N

ORR

LCL

UCL

50
62
44
68
30
53
8
7
11
79
78
34
31
81
57
55
54
57
70
42
28
84
75
34
89
73
20
112

82.0
74.2
75.0
79.4
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The most common grade 3/4 hematologic TEAEs were
neutropenia (62.5%) and anemia (17.9%), and the most
common grade 3/4 nonhematologic TEAE was pneumonia
(13.4%) (Table 3). Forty patients (35.7%) had ≥1 TEAE
leading to reduction of pomalidomide (Table 4). The most
common TEAE leading to pomalidomide dose reduction was
neutropenia (20.5%). Seventy-eight patients (69.6%) had ≥1
TEAE leading to pomalidomide interruption, and 88 (78.6%)
had ≥1 TEAE leading to daratumumab interruption. Pomalidomide and daratumumab dose interruptions due to TEAEs
were most frequently caused by neutropenia (37.5 and
39.3%) and pneumonia (14.3 and 8.9%). Discontinuations of
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Fig. 4 Progression-free survival. a Median PFS was not reached in the ITT population or in patients who relapsed after lenalidomide. Median
PFS was 21.8 months in patients who were refractory to lenalidomide. b Median PFS was not reached in patients whose last prior dose of
lenalidomide was ≤10 mg or in those whose last prior dose was >10 mg. ITT intention-to-treat, LEN lenalidomide, NE not estimable, PFS
progression-free survival.

pomalidomide and daratumumab due to ≥1 TEAE were
reported in ﬁve and eight patients (4.5% and 7.1%),
respectively. Six SPMs were reported: two basal cell carcinomas, one metastatic colon cancer, one hepatic cancer, one
lymphocytic leukemia, and one squamous cell carcinoma of
the skin.
As of 15 October 2018, 108 patients were HRQOL
evaluable. EQ-5D completion rates for each evaluated cycle
(1–6) were ≥88%. Through all six cycles, mean changes
from baseline in EQ-5D index and visual analog scale
health score were stable. Minimum clinically important
improvements in EQ-5D index (≥0.1) and visual analog
scale health score (≥6) were achieved by 28.8% and 39.0%
of patients at cycle 6, respectively. EQ-5D index values
were stable, with a trend toward improvement in usual
activities, pain/discomfort, and anxiety/depression.

Discussion
The results from cohort B in MM-014 demonstrated the
effectiveness and safety of pomalidomide, low-dose dexamethasone, and daratumumab in patients with RRMM
immediately after failure of ﬁrst- or second-line lenalidomide-based treatment. Notably, most patients (62.5%) had
received only one prior line of therapy, and 75.0% were
lenalidomide refractory. ORR, the primary endpoint, was
77.7%. More than half of patients achieved VGPR or better;
responses deepened over time, with 42.5% of patients
reaching their best response after ≥6 months of treatment,
indicating the importance of long-term treatment with this
regimen. Responses persisted in most patients at 1 year.
Half of the patients with VGPR or better and assessable
MRD achieved MRD negativity at the lowest limit of
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Table 3 Select grade 3/4 TEAEs.
TEAEs, n (%)

a

≥1 grade 3/4 TEAEs

Safety population
(N = 112)
104 (92.9)

Grade 3/4 hematologic TEAEsb
Neutropenia
Febrile neutropenia

70 (62.5)
11 (9.8)

Anemia

20 (17.9)

Thrombocytopenia

14 (12.5)

Leukopenia

6 (5.4)

Grade 3/4 nonhematologic TEAEsb
Infections and infestations
Pneumonia

35 (31.3)
15 (13.4)

Inﬂuenza

5 (4.5)

Sepsis

5 (4.5)

Parainﬂuenzae virus

4 (3.6)

Back pain

6 (5.4)

Insomnia

6 (5.4)

Atrial ﬁbrillation

5 (4.5)

Dyspnea

5 (4.5)

Hyperglycemia

5 (4.5)

Hypokalemia

5 (4.5)

Hypertension

5 (4.5)

Chronic obstructive pulmonary disease

4 (3.6)

Fatigue

4 (3.6)

Hypophosphatemia

4 (3.6)

TEAE treatment-emergent adverse event.
a

TEAE severity was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events version 4.03.
Reported in ≥3% of the safety population.

b

quantiﬁcation. At 1 year, 75.1% of patients were alive and
progression free. The reported safety proﬁle was consistent
with the known toxicities of the individual agents, and
patient HRQOL was either maintained or demonstrated
signs of improvement.
Pomalidomide, low-dose dexamethasone, and daratumumab beneﬁtted most evaluated patient subgroups.
ORR similar to that of the ITT population was achieved
regardless of number of prior lines of therapy (one or two),
refractoriness to lenalidomide, or previous bortezomib
exposure. Of note, patients whose last prior dose of lenalidomide was ≤10 mg derived greater beneﬁt from subsequent pomalidomide therapy than patients whose last
prior dose was >10 mg, and patients who were treated with
lenalidomide for >2 years had improved ORR vs patients
who were treated for ≤2 years. More than 50% of patients
with high-risk cytogenetics achieved ORR, indicating
activity with this pomalidomide-based regimen in this difﬁcult to treat population; further analyses in patients with
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high-risk cytogenetics are warranted. Finally, it must be
noted that ORRs exceeding 90% (without the 95% conﬁdence intervals crossing the ITT ORR of 77.7%) were
observed in patients with calculated Revised International
Staging System I and patients who were treated with lenalidomide for >2 years, suggesting that patients with these
characteristics could derive the greatest beneﬁt with this
regimen.
Despite acquired resistance to lenalidomide in the
immediate prior line of therapy, pomalidomide combined
with daratumumab and dexamethasone led to deep and
durable responses. Findings from the exploratory immune
proﬁle analysis demonstrated the beneﬁts of maintaining
continuous immunomodulation via sequencing pomalidomide immediately after lenalidomide, even in the context of
lenalidomide resistance. The combination of pomalidomide,
low-dose dexamethasone, and daratumumab did not impair
the innate or adaptive immune compartments and demonstrated signiﬁcant proliferative activity in CD4, CD8, and
NK-cell subsets [32]. The latter ﬁnding indicates that
pomalidomide-based treatment could offset daratumumabmediated loss of NK cells [30]. Furthermore, changes from
baseline, including decreases in naive T cells and selective
increases in proliferative and activated T cells (with no
increase in regulatory T cells), indicated a shift toward
immunocompetence enhancement. Likewise, an exploratory
immune proﬁle analysis of cohort A demonstrated that
pomalidomide plus low-dose dexamethasone increased
CD3+ and CD8+ T-cell populations, while CD4+ T-cell
populations remained unchanged [33]. The immune stimulation imparted by pomalidomide-based treatment in
patients who relapsed after or became refractory to lenalidomide supports previous data indicating that pomalidomide is pharmacologically distinct from lenalidomide and
active in the setting of lenalidomide resistance [12–20].
In addition, the higher 1-year PFS rate and ORR reported in
patients who were treated with lenalidomide for >2 years vs
those treated for ≤2 years, as well as the fact that responses
deepened over time, may be suggestive of the beneﬁts of
uninterrupted treatment with immunomodulatory agents
and tolerance to their related AEs. In clinical practice,
physicians may be inclined to change class following PD
on or after lenalidomide. However, these ﬁndings add
to the growing body of evidence indicating that
pomalidomide-based regimens, including pomalidomide
with daratumumab, can overcome early-line resistance or
refractoriness to lenalidomide, demonstrating that there is
no evidence-based need to replace an IMiD agent with
another drug class after PD on lenalidomide. Recent results
with iberdomide, a novel cereblon E3 ligase modulator with
enhanced tumoricidal and immunomodulatory activity,
further support the beneﬁcial role of continued immunomodulation in MM [34, 35].
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Table 4 TEAEs leading to dose
modiﬁcations.
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TEAEs, n (%)

Safety population (N = 112)
Pomalidomide
(n = 112)

Patients with ≥1 TEAE leading to 40 (35.7)
dose reduction

Low-dose
dexamethasone
(n = 112)

Daratumumab
(n = 112)

42 (37.5)

—b

2 (1.8)

—b

Hematologic TEAEsa
Neutropenia

23 (20.5)

Nonhematologic TEAEsa
Insomnia

0

11 (9.8)

—b

Hyperglycemia

0

4 (3.6)

—b

Peripheral edema

0

4 (3.6)

—b

Patients with ≥1 TEAE leading to 78 (69.6)
interruption

74 (66.1)

88 (78.6)

38 (33.9)

44 (39.3)

Hematologic TEAEsa
Neutropenia

42 (37.5)

Febrile neutropenia

6 (5.4)

6 (5.4)

3 (2.7)

Neutrophil count
decreased

2 (1.8)

2 (1.8)

4 (3.6)

Thrombocytopenia

6 (5.4)

5 (4.5)

5 (4.5)

Leukopenia

3 (2.7)

3 (2.7)

5 (4.5)

40 (35.7)

36 (32.1)

33 (29.5)

Nonhematologic TEAEsa
Infections
Pneumonia

16 (14.3)

13 (11.6)

10 (8.9)

Upper respiratory tract
infection

8 (7.1)

7 (6.3)

7 (6.3)

Inﬂuenza

6 (5.4)

5 (4.5)

3 (2.7)

Bronchitis

3 (2.7)

4 (3.6)

3 (2.7)

Dyspnea

4 (3.6)

4 (3.6)

5 (4.5)

Cough

3 (2.7)

3 (2.7)

4 (3.6)

Infusion-related reaction
Patients with ≥1 TEAE leading to
discontinuationc

0
5 (4.5)

0
8 (7.1)

26 (23.2)
8 (7.1)

TEAE treatment-emergent adverse event.
a

Reported in ≥3% of patients for any drug. Patients may have had ≥1 TEAE leading to the dose modiﬁcation.

b

Per protocol, daratumumab dose reductions were not allowed.

c

All TEAEs leading to discontinuation of each respective drug were reported in <3% of patients.

Patients refractory to lenalidomide have been largely
excluded from randomized trials evaluating investigational regimens against the standard control regimen of
lenalidomide and dexamethasone. However, several phase
3 trials included patients refractory to lenalidomide,
such as ENDEAVOR (carﬁlzomib plus dexamethasone;
25%), ARROW (once weekly carﬁlzomib plus dexamethasone; 74%), OPTIMISMM (PVd; 70%), CASTOR
(daratumumab plus Vd; 28%), ELOQUENT-3 (elotuzumab, pomalidomide, and dexamethasone; 87%), and
ICARIA (isatuximab, pomalidomide, and dexamethasone;
93%) [25, 36–44]. CASTOR reported ORR in the subgroup of patients refractory to lenalidomide (at last prior
line of therapy); ORR was 80.5% with daratumumab plus

Vd. ENDEAVOR, OPTIMISMM, and CASTOR reported
median PFS values ranging from 8.6 to 9.5 months in
lenalidomide-refractory patients who received the investigational treatments. These outcomes are consistent with
ORR and median PFS values of the ITT populations
from clinical trials that included a high percentage of
lenalidomide-refractory patients (e.g., ARROW, OPTIMISMM, ELOQUENT-3, and ICARIA); among patients
in the investigational arms, ORR ranged from 53.3 to
82.2%, and median PFS ranged from 10.3 to 11.5 months.
While cross-trial comparisons should be interpreted
cautiously, the ORR of 76.2% and 1-year PFS rate
of 72.4% reported in lenalidomide-refractory patients
in the current study is encouraging in the context of
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available data from phase 3 RRMM trials that included
lenalidomide-refractory patients.
The combination of pomalidomide, low-dose dexamethasone, and daratumumab is currently approved in the
United States for the treatment of patients with RRMM and
≥2 prior therapies, including lenalidomide and a PI, based
on results of the phase 1b MMY1001 trial in heavily pretreated patients with RRMM (median prior lines of therapy,
four) [21, 22, 31]. In contrast, patients in our trial were
required to have had one or two prior lines of therapy, and
62.5% of patients had only one prior therapy. It is notable
that ORR in this study was higher (77.7 vs 60.2%) and the
rate of grade 3/4 neutropenia was lower (62.5 vs 76.7%).
Importantly, in the current study, median PFS was not
reached, and the 1-year PFS rate was 75.1%, indicating the
beneﬁt of initiating this treatment in earlier lines of therapy.
Recently published ﬁndings from the daratumumab,
carﬁlzomib, and dexamethasone (DKd) arm of the
MMY1001 study and the phase 3 CANDOR study provide
valuable context regarding use of daratumumab-containing
regimens in this setting [45, 46]. In MMY001, patients with
RRMM (N = 85) and a median of two prior lines of therapy,
including bortezomib and an immunomodulatory drug,
received DKd [45]. Overall, 60% of patients were lenalidomide refractory. The 1-year PFS rate was 74% and ORR
was 84%. Rates of grade 3/4 neutropenia, thrombocytopenia, and lymphopenia were 21%, 31%, and 24%, respectively. Twenty-four patients had cardiac TEAEs, mostly
grade 3/4, which improved with carﬁlzomib interruption.
Infusion-related reactions were common (43–60%). In
CANDOR, patients with RRMM and one to three prior
lines of therapy were randomized 2:1 to DKd (n = 312) or
carﬁlzomib plus dexamethasone (Kd; n = 154) [46]. Overall, 42.3% of patients had previous exposure to lenalidomide and 33% were refractory to lenalidomide. Median PFS
was not reached with DKd vs 15.8 months with Kd, and
ORR was 84.3% vs 74.7% (p = 0.00040). Grade ≥3 cardiac
failure was reported in 3.9% and 8.5% of patients receiving
DKd and Kd, respectively.
Despite the higher proportion of lenalidomide-refractory
patients in cohort B of MM-014, key efﬁcacy outcomes
between DKd in the MMY1001 and CANDOR trials and
pomalidomide, low-dose dexamethasone, and daratumumab
were similar. In addition, while the rate of grade 3/4 neutropenia in the present study was higher than in MMY1001,
rates of grade 3/4 thrombocytopenia and lymphopenia were
lower. Notably, infusion-related reactions also occurred less
frequently in the present study (30.4%) than in MMY1001.
Taken together with results from cohort B, these ﬁndings
demonstrate that the pomalidomide, low-dose dexamethasone, and daratumumab regimen is an effective
treatment option in the setting of lenalidomide-refractory
disease. Findings from ongoing phase 3 trials evaluating
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pomalidomide-based regimens with monoclonal antibodies
will provide further context. Interim results of the ICARIA
trial evaluating pomalidomide, low-dose dexamethasone,
and isatuximab in a 100% lenalidomide-exposed and 93%
lenalidomide-refractory patient population (median, three
prior lines of therapy) demonstrated signiﬁcantly longer
PFS (median, 11.5 vs 6.5 months; p = 0.001) and signiﬁcantly higher ORR (60.4% vs 35.3%; p < 0.0001) compared with pomalidomide and low-dose dexamethasone
[43, 44].
In clinical practice, physicians may be inclined to
switch away from the immunomodulatory agent drug class
after lenalidomide-based treatment failure. These ﬁndings
demonstrate that pomalidomide, low-dose dexamethasone,
and daratumumab is a safe and effective treatment for
patients with RRMM immediately following disease progression on or after lenalidomide. These data also continue
to support the integration of pomalidomide-based regimens
as early as second line in the management of RRMM, even
in patients refractory to lenalidomide.
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